Cortechs.ai Expands Partnership with Strategic Radiology to Advance Imaging Innovation Across Private Practices

San Diego, CA – Cortechs.ai, a leading provider of AI-powered quantitative imaging solutions, is proud to announce the expansion of its partnership with Strategic Radiology, a coalition of 47 independent, radiologist-owned practices serving over 300 hospitals and 450 imaging centers across 30 states.  

Building on a longstanding collaboration around NeuroQuant, Cortechs.ai and Strategic Radiology have now broadened their alliance to include Cortechs.ai’s full suite of imaging solutions, including OnQ Prostate, NeuroQuant MS, NeuroQuant Brain Tumor, and more. 

“Strategic Radiology has always been a forward-thinking coalition, and we’re thrilled to deepen our relationship,” said Kyle Frye, CEO of Cortechs.ai. “By expanding our partnership beyond NeuroQuant, we’re empowering Strategic Radiology members with a full spectrum of imaging tools that support better diagnostics, improved outcomes, and more efficient care delivery. This is a strategic win for both organizations and for the patients we ultimately serve.” 

This expanded partnership offers preferred pricing incentives to Strategic Radiology member practices, enabling easier access to Cortechs.ai’s portfolio through Strategic Radiology’s group purchasing infrastructure. The collaboration is designed to accelerate adoption, standardize imaging workflows, and enhance clinical quality across Strategic Radiology’s national network. 

“Strategic Radiology is committed to advancing innovation that strengthens independent private practice and improves patient care,” said Scott Bundy, MD, FACR, CEO and Chair of the Board, Strategic Radiology. “Expanding our group purchasing agreement with Cortechs.ai gives our member practices more cost-effective access to proven AI solutions that enhance diagnostic accuracy, streamline workflows, and reinforce our coalition’s focus on clinical quality and physician-led care.” 

The renewed partnership aligns with Strategic Radiology’s mission to maintain autonomy while leveraging shared resources, proprietary analytics, and a unique Patient Safety Organization (PSO) focused on imaging quality. Cortechs.ai’s solutions complement these efforts by offering quantifiable insights that support consistency and clinical decision-making to deliver confident, data-driven care. 

About Cortechs.ai 

Cortechs.ai is a leader in AI applications in radiology. Cortechs.ai uses cutting-edge technologies in medical imaging to revolutionize disease screening and early detection so patients can enjoy longer, healthier lives. The company develops and markets breakthrough medical device software that quantifies and tracks neurodegenerative diseases and assists in the detection of clinically significant cancer. Cortechs.ai’s industry-leading brain imaging software provides radiologists, neurologists, oncologists, and clinical researchers worldwide with a convenient and cost-effective way to quantify brain structures for assessing Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma, and other brain abnormalities. The company has FDA-cleared products for use in helping the diagnosis and follow-up of neurodegenerative and traumatic brain conditions, as well as prostate cancer. Please visit www.cortechs.ai for further information and follow us on Twitter, LinkedIn, and Facebook. 

For more information, please contact: 

___________ 

info@cortechs.ai   

+1 858 459 9700 

About Strategic Radiology 

Strategic Radiology is a coalition of independent, privately owned radiology practices that collaborate to improve quality, share best practices, and maintain clinical autonomy. Representing over 2,200 radiologists nationwide, SR offers its members access to proprietary tools, executive forums, and a unique Patient Safety Organization dedicated to imaging excellence. 

More Resources

08/19/2026

Brain Metastases Imaging Insights from SNO/ASCO 2026

Explore key insights from SNO/ASCO 2026 on brain metastases imaging, including lesion tracking, volumetric analysis, SRS workflows, and automated segmentation.

08/18/2026

Cortechs.ai Announces FDA Clearance for NeuroQuant® PET: Advancing Molecular Imaging for Cognitive Impairment

NeuroQuant® PET receives FDA 510(k) clearance, advancing quantitative PET imaging for cognitive impairment.

08/04/2026

Cortechs.ai Expands European CE Marking Across AI Imaging Platform, Accelerating Global Growth

Cortechs.ai expands EU CE Marking for the latest NeuroQuant®, NeuroQuant® Brain Tumor, and OnQ™ Prostate, advancing global AI imaging innovation

07/29/2026

Read Your Segmentations in the Same Space You Read the Study: Native Space Outputs in NeuroQuant v5.3.0

Review lesion segmentations directly on your original MRI images with NeuroQuant® v5.3.0.

07/23/2026

What AAIC 2026 Told Us About the Future of Dementia Imaging — And Where NeuroQuant Fits

Quantitative MRI brain volumetry with NeuroQuant.

07/09/2026

Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration

Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai’s health system network
Scroll to Top